Breaking the spell: Combating multidrug resistant 'superbugs'

Frontiers in Microbiology

Volumn 7, Issue FEB, 2016, Pages

  Khan, Shahper N ^a   Khan, Asad U ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Drug development; Functional genomics; In vivo imaging; Multidrug resistant; Network pharmacology

Indexed keywords

AMIKACIN; CETHROMYCIN; CYCLOSERINE; ENDOTOXIN; ERAVACYCLINE; FIBRONECTIN BINDING PROTEIN; FUSIDATE SODIUM; GENTAMICIN; GRAMICIDIN S; LANOPEPDEN; LEVOFLOXACIN; OMADACYCLINE; OMIGANAN; PEPTIDE; PEXIGANAN; PLAZOMICIN; POLYMYXIN; RADEZOLID; SOLITHROMYCIN; TEDIZOLID; TETRACYCLINE; VACCINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; BIOLUMINESCENCE IMAGING; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECIUM; FUNCTIONAL GENOMICS; HUMAN; IC50; IMAGING; IMMUNE RESPONSE; KLEBSIELLA PNEUMONIAE; MEDICINAL CHEMISTRY; MULTIDRUG RESISTANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION;

EID: 84962061598     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.00174     Document Type: Review

References (109)

1. Aggen, J. B., Armstrong, E. S., Goldblum, A. A., Dozzo, P., Linsell, M. S., Gliedt, M. J., et al. (2010). Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54, 4636-4642. doi: 10.1128/AAC.00572-10
2. Alekshun, M. N., and Levy, S. B. (2007). Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037-1050. doi: 10.1016/j.cell.2007.03.004
3. Arciola, C. R., Speziale, P., and Montanaro, L. (2009). Perspectives on DNA vaccines. Targeting staphylococcal adhesins to prevent implant infections. Int. J. Artif. Organs 32, 635-641.
4. Armstrong, E. S., and Miller, G. H. (2010). Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr. Opin. Microbiol. 13, 565-573. doi: 10.1016/j.mib.2010.09.004
5. Bagnoli, F., Fontana, M. R., Soldaini, E., Mishra, R. P., Fiaschi, L., Cartocci, E., et al. (2015). Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 112, 3680-3685. doi: 10.1073/pnas.1424924112
6. Bandow, J. E., Becher, D., Büttner, K., Hochgräfe, F., Freiberg, C., Brötz, H., et al. (2003). The role of peptide deformylase in protein biosynthesis: a proteomic study. Proteomics 3, 299-306. doi: 10.1002/pmic.200390043
7. Bentolila, L. A., Ebensteinn, Y., and Weiss, S. (2009). Quantum dots for in vivo small-animal imaging. J. Nucl. Med. 50, 493-496. doi: 10.2967/jnumed.108.053561
8. Bhaumik, S., and Gambhir, S. (2002). Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl. Acad. Sci. U.S.A. 99, 377-382. doi: 10.1073/pnas.012611099
9. Bommarius, B., and Kalman, D. (2009). Antimicrobial and host defense peptides for therapeutic use against multidrug-resistant pathogens: new hope on the horizon. IDrugs 12, 376-380.
10. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., et al. (2009). Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-2. doi: 10.1086/595011
11. Brolund, A., Sundqvist, M., Kahlmeter, G., and Grape, M. (2010). Molecular characterisation of trimethoprim resistance in Escherichia coli and Klebsiella pneumoniae during a two year intervention on trimethoprim use. PLoS ONE 5:e9233. doi: 10.1371/journal.pone.0009233
12. Brötz-Oesterhelt, H., Bandow, J. E., and Labischinski, H. (2005). Bacterial proteomics and its role in antibacterial drug discovery. Mass. Spectrom. Rev. 24, 549-565. doi: 10.1002/mas.20030
13. Brunschweiger, A., and Hall, J. (2012). A decade of the human genome sequence-how does the medicinal chemist benefit? Chem. Med. Chem. 7, 194-203. doi: 10.1002/cmdc.201100498
14. Cantas, L., Shah, S. Q., Cavaco, L. M., Manaia, C. M., Walsh, F., Popowska, M., et al. (2013). A brief multi-disciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiota. Front. Microbiol. 4:96. doi: 10.3389/fmicb.2013.00096
15. Carattoli, A. (2009). Resistance plasmid families in Enterobacteriaceae. Antimicrob. Agents Chemother. 53, 2227-2238. doi: 10.1128/AAC.01707-08
16. Carragher, N. O., Brunton, V. G., and Frame, M. C. (2012). Combining imaging and pathway profiling: an alternative approach to cancer drug discovery. Drug Discov. Today 17, 203-214. doi: 10.1016/j.drudis.2012.02.002
17. Coban, C., Koyama, S., Takeshita, F., Akira, S., and Ishii, K. J. (2008). Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin. 4, 453-456. doi: 10.4161/hv.4.6.6200
18. Cohen, J. M., Chimalapati, S., and de Vogel, C. (2012). Contributions of capsule, lipoproteins and duration of colonisation towards the protective immunity of prior Streptococcus pneumoniae nasopharyngeal colonisation. Vaccine 30, 4453-4459. doi: 10.1016/j.vaccine.2012.04.080
19. Coto-García, A. M., Sotelo-González, E., and Fernández-Argüelles, M. T. (2011). Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal. Bioanal. Chem. 399, 29-42. doi: 10.1007/s00216-010-4330-3
20. Couce, A., and Blázquez, J. (2009). Side effects of antibiotics on genetic variability. FEMS Microbiol. Rev. 33, 531-538. doi: 10.1111/j.1574-6976.2009.00165.x
21. Cudic, M., Lockatell, C. V., Johnson, D. E., and Otvos, L. Jr. (2003). In vitro and in vivo activity of an antibacterial peptide analog against uropathogens. Peptides 24, 807-820. doi: 10.1016/S0196-9781(03)00172-4
22. Dandekar, T., and Dandekar, G. (2010). Pharmacogenomic strategies against microbial resistance: from bright to bleak to innovative. Pharmacogenomics 11, 1193-1196. doi: 10.2217/pgs.10.18
23. De Cristóbal, R. E., Vincent, P. A., and Salomón, R. A. (2008). A combination of sbmA and tolC mutations in Escherichia coli K-12 Tn10-carrying strains results in hypersusceptibility to tetracycline. J. Bacteriol. 190, 1491-1494. doi: 10.1128/JB.01844-07
24. De Gelder, L., Ponciano, J. M., Joyce, P., and Top, E. M. (2007). Stability of a promiscuous plasmid in different hosts: no guarantee for a long-term relationship. Microbiology 153, 452-463. doi: 10.1099/mic.0.2006/001784-0
25. Del Olmo, A., Morales, P., and Nuñez, M. (2009). Bactericidal activity of lactoferrin and its amidated and pepsin-digested derivatives against Pseudomonas fluorescens in ground beef and meat fractions. J. Food Prot. 72, 760-765.
26. Delfani, S., Imani Fooladi, A. A., Mobarez, A. M., Emaneini, M., Amani, J., and Sedighian, H. (2015). In silico analysis for identifying potential vaccine candidates against Staphylococcus aureus. Clin. Exp. Vaccine Res. 1, 99-106. doi: 10.7774/cevr.2015.4.1.99
27. Denome, S. A., Elf, P. K., Henderson, T. A., Nelson, D. E., and Young, K. D. (1999). Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J. Bacteriol. 181, 3981-3993.
28. DeVito, J. A., Mills, J. A., Liu, V. G., Agarwal, A., Sizemore, C. F., Yao, Z., et al. (2002). An array of targetspecific screening strains for antibacterial discovery. Nat. Biotechnol. 20, 478-483. doi: 10.1038/nbt0502-478
29. Dewan, V., Reader, J., and Forsyth, K. M. (2014). Role of aminoacyl-tRNA synthetases in infectious diseases and targets for therapeutic development. Top. Curr. Chem. 344, 293-329. doi: 10.1007/128_2013_425
30. Drew, R. H. (2009). Antimicrobial stewardship programs: how to start and steer a successful program. J. Manag. Care Pharm. 15, S18-S23. doi: 10.1007/128_2013_425
31. Durante-Mangoni, E., and Zarrilli, R. (2011). Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 6, 407-422. doi: 10.2217/fmb.11.23
32. Fajardo, A., Martínez-Martín, N., Mercadillo, M., Galán, J. C., Ghysels, B., Matthijs, S., et al. (2008). The neglected intrinsic resistome of bacterial pathogens. PLoS ONE 3:e1619. doi: 10.1371/journal.pone.0001619
33. Fjell, C. D., Hiss, J. A., Hancock, R. E., and Schneider, G. (2011). Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11, 37-51. doi: 10.1038/nrd3591
34. Fleischmann, R. D., Adams, M. D., White, O., Clayton, R. A., Kirkness, E. F., Kerlavage, A. R., et al. (1995). Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496-512. doi: 10.1126/science.7542800
35. Fornili, S., Pizzi, R., and Rebeccani, D. (2010). Conformational analysis of a synthetic antimicrobial peptide in water and membrane-mimicking solvents: a molecular dynamics simulation study. Int. J. Pept. Res. Ther. 16, 223-231. doi: 10.1007/s10989-010-9211-2
36. Forsyth, R. A., Haselbeck, R. J., Ohlsen, K. L., Yamamoto, R. T., Xu, H., Trawick, J. D., et al. (2002). A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387-1400. doi: 10.1046/j.1365-2958.2002.02832.x
37. Freiberg, C., Brunner, N. A., Schiffer, G., Lampe, T., Pohlmann, J., Brands, M., et al. (2004). Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J. Biol. Chem. 279, 26066-26073. doi: 10.1074/jbc. M402989200
38. Freiberg, C., Fischer, H. P., and Brunner, N. A. (2005). Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants. Antimicrob. Agents Chemother. 49, 749-759. doi: 10.1128/AAC.49.2.749-759.2005
39. García-Quintanilla, M., Pulido, M. R., Pachón, J., and McConnell, M. J. (2014). Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection. PLoS ONE 9:e114410. doi: 10.1371/journal.pone.0114410
40. Girgis, H. S., Hottes, A. K., and Tavazoie, S. (2009). Genetic architecture of intrinsic antibiotic susceptibility. PLoS ONE 4:e5629. doi: 10.1371/journal.pone.0005629
41. Goldstein, E. J., Citron, D. M., Tyrrell, K. L., and Merriam, C. V. (2013). Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob. Agents Chemother. 57, 2401-2404. doi: 10.1128/AAC.02580-12
42. Gootz, T. D. (2010). The global problem of antibiotic resistance. Crit. Rev. Immunol. 30, 79-93. doi: 10.1615/CritRevImmunol.v30.i1.60
43. Gordon, Y. J., Romanowski, E. G., and McDermott, A. M. (2005). A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30, 505-515. doi: 10.1080/02713680590968637
44. Greenberg, D. E., Marshall-Batty, K. R., Brinster, L. R., Zarember, K. A., Shaw, P. A., Mellbye, B. L., et al. (2010). Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J. Infect. Dis. 201, 1822-1830. doi: 10.1086/652807
45. Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., et al. (2012). Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother. 56, 2559-2564. doi: 10.1128/AAC.06187-11
46. Guilhelmelli, F., Vilela, N., Albuquerque, P., Derengowski Lda, S., Silva-Pereira, I., and Kyaw, C. M. (2013). Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front. Microbiol. 4:353. doi: 10.3389/fmicb.2013.00353
47. Gwynn, M. N., Portnoy, A., Rittenhouse, S. F., and Payne, D. J. (2010). Challenges of antibacterial discovery revisited. Ann. N. Y. Acad. Sci. 213, 5-19. doi: 10.1111/j.1749-6632.2010.05828.x
48. Heine, H. S., Marchand, C. L., Miller, L., Halasohoris, S., Jakielaszek, C., Easom, E., et al. (2011). "Susceptibility testing of a novel mechanism antibacterial GSK2251052 against category A/B bacterial biothreat agents, "in Proceedings of the 51st Annual ICAAC, September 12-15. Chicago, IL.
49. Hopkins, A. L. (2007). Network pharmacology. Nat. Biotechnol. 25, 1110-1111. doi: 10.1038/nbt1007-1110
50. Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690. doi: 10.1038/nchembio.118
51. Hopkins, A. L., Mason, J. S., and Overington, J. P. (2006). Can we rationally design promiscuous drugs. Curr. Opin. Struct. Biol. 16, 127-136. doi: 10.1016/j.sbi.2006.01.013
52. Janoir, C., Zeller, V., Kitzis, M. D., Moreau, N. J., and Gutmann, L. (1996). High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40, 2760-2764. PMID: 9124836
53. Johansen, H. K., and Gøtzsche, P. C. (2015). Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 8:CD001399. doi: 10.1002/14651858.CD001399
54. Jones, T. R., Carpenter, A. E., Lamprecht, M. R., Moffat, J., Silver, S. J., Grenier, J. K., et al. (2009). Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc. Natl. Acad. Sci. U.S.A. 106, 1826-1831. doi: 10.1073/pnas.0808843106
55. Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., and Shoichet, B. K. (2007). Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206. doi: 10.1038/nbt1284
56. Khan, A. U., and Nordmann, P. (2012a). NDM-1-producing Enterobacter cloacae and Klebsiella pneumoniae from diabetic foot ulcers in India. J. Med. Microbiol. 61, 454-456. doi: 10.1099/jmm.0.039008-0
57. Khan, A. U., and Nordmann, P. (2012b). Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed. Scand. J. Infect. Dis. 44, 531-535. doi: 10.3109/00365548.2012.669046
58. Kuklin, N. A., Clark, D. J., Secore, S., Cook, J., Cope, L. D., McNeely, T., et al. (2006). A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macques and specific increased survival in a murine model of S. aureus sepsis. Infect. Immun. 74, 2215-2223. doi: 10.1128/IAI.74.4.2215-2223.2006
59. Labro, M. T., and Bryskier, J. M. (2014). Antibacterial resistance: an emerging 'zoonosis?' Expert Rev. Anti Infect. Ther. 12, 1441-1461. doi: 10.1586/14787210.2014.976611
60. Lange, R. P., Locher, H. H., Wyss, P. C., and Then, R. L. (2007). The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Des. 13, 3140-3154. doi: 10.2174/138161207782110408
61. Leevy, W. M., Lambert, T. N., Johnson, J. R., Morris, J., and Smith, B. D. (2008). Quantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging. Chem. Commun. 28, 2331-2333. doi: 10.1039/b803590c
62. Levy, S. B., and Marshall, B. (2004). Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10, S122-S129. doi: 10.1038/nm1145
63. Li, J. M., Wang, Y. Y., and Zhao, M. X. (2012). Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 33, 2780-2790. doi: 10.1016/j.biomaterials.2011.12.035
64. Lipsky, B. A., Holroyd, K. J., and Zasloff, M. (2008). Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47, 1537-1545. doi: 10.1086/593185
65. Liu, J., Dehbi, M., Moeck, G., Arhin, F., Bauda, P., Bergeron, D., et al. (2004). Antimicrobial drug discovery through bacteriophage genomics. Nat. Biotechnol. 22, 185-191. doi: 10.1038/nbt932
66. Livermore, D. M., Mushtaq, S., Warner, M., Zhang, J. C., Maharjan, S., Doumith, M., et al. (2011). Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66, 48-53. doi: 10.1093/jac/dkq408
67. Lupetti, A., Welling, M. M., Pauwels, E. K., and Nibbering, P. H. (2003). Radiolabelled antimicrobial peptides for infection detection. Lancet Infect. Dis. 3, 223-229. doi: 10.1016/S1473-3099(03)00579-6
68. Mandal, T. K., and Parvin, N. (2011). Rapid detection of bacteria by carbon quantum dots. J. Biomed. Nanotechnol. 7, 846-848. doi: 10.1166/jbn.2011.1344
69. McDevitt, D., Payne, D. J., Holmes, D. J., and Rosenberg, M. (2002). Novel targets for the future development of antibacterial agents. Symp. Ser. Soc. Appl. Microbiol. 31, 28S-34S. doi: 10.1046/j.1365-2672.92.5s1.16.x
70. Melendez-Alafort, L., Rodriguez-Cortes, J., Ferro-Flores, G., Arteaga De Murphy, C., Herrera-Rodríguez, R., Mitsoura, E., et al. (2004). Biokinetics of Tc-99m-UBI 29-41 in humans. Nucl. Med. Biol. 31, 373-379. doi: 10.1016/j.nucmedbio.2003.10.005
71. Mendes, R. E., Biedenbach, D. J., Alley, M. R. K., Sader, H. S., and Jones, R. N. (2013). Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative gram-negative bacilli. Antimicrob. Agents Chemother. 57, 2849-2857. doi: 10.1128/AAC.00160-13
72. Morar, M., and Wright, G. D. (2010). The genomic enzymology of antibiotic resistance. Annu. Rev. Genet. 44, 25-51. doi: 10.1146/annurev-genet-102209-163517
73. Morphy, R., and Rankovic, Z. (2006). The physicochemical challenges of designing multiple ligands. J. Med. Chem. 49, 4961-4970. doi: 10.1021/jm0603015
74. Morphy, R., and Rankovic, Z. (2007). Fragments, network biology and designing multiple ligands. Drug Discov. Today 12, 156-160. doi: 10.1016/j.drudis.2006.12.006
75. Motter, A. E. (2010). Improved network performance via antagonism: from synthetic rescues to multi-drug combinations. Bioessays 32, 236-245. doi: 10.1002/bies.200900128
76. Murray, J. L., Kwon, T., and Marcotte, E. M. (2015). Intrinsic antimicrobial resistance determinants in the superbug Pseudomonas aeruginosa. MBio 6:e01603-15. doi: 10.1128/mBio.01603-15
77. Nan, Y. H., Bang, J. K., Jacob, B., Park, I. S., and Shin, S. Y. (2012). Prokaryotic selectivity and LPS-neutralizing activity of short antimicrobial peptides designed from the human antimicrobial peptide LL-37. Peptides 35, 239-247. doi: 10.1016/j.peptides.2012.04.004
78. Ng, K. P., Ebrahem, Q., Negrotto, S., Mahfouz, R. Z., Link, K. A., Hu, Z., et al. (2011). p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 25, 1739-1750. doi: 10.1038/leu.2011.159
79. Nordmann, P., Dortet, L., and Poirel, L. (2012). Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol. Med. 18, 263-272. doi: 10.1016/j.molmed.2012.03.003
80. Nordmann, P., Poirel, L., Walsh, T. R., and Livermore, D. M. (2011). The emerging NDM carbapenemases. Trends Microbiol. 19, 588-595. doi: 10.1016/j.tim.2011.09.005
81. O'Dwyer, K., Spivak, A. T., Ingraham, K., Min, S., Holmes, D. J., Jakielaszek, C., et al. (2015). Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob. Agents Chemother. 59, 289-298. doi: 10.1128/AAC.03774-14
82. Oliver, A., Cantón, R., Campo, P., Baquero, F., and Blázquez, J. (2000). High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251-1254. doi: 10.1126/science.288.5469.1251
83. Onaizi, S. A., and Leong, S. S. (2011). Tethering antimicrobial peptides: current status and potential challenges. Biotechnol. Adv. 29, 67-74. doi: 10.1016/j.biotechadv.2010.08.012
84. Otto, M. (2010). Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin. Biol. Ther. 10, 1049-1059. doi: 10.1517/14712598.2010.495115
85. Paolini, G. V., Shapland, R. H., van Hoorn, W. P., Mason, J. S., and Hopkins, A. L. (2006). Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815. doi: 10.1038/nbt1228
86. Paroo, Z., Bollinger, R. A., Braasch, D. A., Richer, E., Corey, D. R., Antich, P. P., et al. (2004). Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol. Imaging 3, 117-124. doi: 10.1162/1535350041464865
87. Pitout, J. D., and Laupland, K. B. (2008). Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8, 159-166. doi: 10.1016/S1473-3099(08)70041-0
88. Probst, J., Dembski, S., Milde, M., and Rupp, S. (2012). Luminescent nanoparticles and their use for in vitro and in vivo diagnostics. Expert Rev. Mol. Diagn. 12, 49-64. doi: 10.1586/ERM.11.86
89. Roda, A., and Guardigli, M. (2012). Analytical chemiluminescence and bioluminescence: latest achievements and new horizons. Anal. Bioanal. Chem. 402, 69-76. doi: 10.1007/s00216-011-5455-8
90. Shkreta, L., Talbot, B. G., Diarra, M. S., and Lacasse, P. (2004). Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 23, 114-126. doi: 10.1016/j.vaccine.2004.05.002
91. Smith, P. R., Le Breton, A., Horsberg, T. E., and Corsin, F. (2009). "Guidelines for antimicrobial use in aquaculture, "in Guide to Antimicrobial Use in Animals, eds L. Guardabassi, L. B. Jensen, and H. Kruse (Oxford: Blackwell Publishing Ltd), 207-218. doi: 10.1002/9781444302639
92. Sommer, M. O., Dantas, G., and Church, G. M. (2009). Functional characterization of the antibiotic resistance reservoir in the human microflora. Science 325, 1128-1131. doi: 10.1126/science.1176950
93. Strebhardt, K., and Ullrich, A. (2008). Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473-480. doi: 10.1038/nrc2394
94. Sutcliffe, J. A. (2011). Antibiotics in development targeting protein synthesis. Ann. N. Y. Acad. Sci. 1241, 122-152. doi: 10.1111/j.1749-6632.2011.06323.x
95. Sutcliffe, J. A., O'Brien, W., Fyfe, C., and Grossman, T. H. (2013). Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 57, 5548-5558. doi: 10.1128/AAC.01288-13
96. Tacconelli, E. (2009). Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr. Opin. Infect. Dis. 22, 352-358. doi: 10.1097/QCO.0b013e32832d52e0
97. Tang, D., Devit, M., and Johnston, S. A. (1992). Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154. doi: 10.1038/356152a0
98. Tavares, L. S., Silva, C. S., de Souza, V. C., da Silva, V. L., Diniz, C. G., and Santos, M. O. (2013). Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides. Front. Microbiol. 4:412. doi: 10.3389/fmicb.2013.00412
99. Tenover, F. C., Tickler, I., Armstrong, E. S., Kubo, A., Lopez, S., Persing, D. H., et al. (2011). Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int. J. Antimicrob. Agents 38, 352-354. doi: 10.1016/j.ijantimicag.2011.05.016
100. Thaller, M. C., Migliore, L., Marquez, C., Tapia, W., Cedeño, V., Rossolini, G. M., et al. (2010). Tracking acquired antibiotic resistance in commensal bacteria of Galápagos land iguanas: no man, no resistance. PLoS ONE 5:e8989. doi: 10.1371/journal.pone.0008989
101. Tian, X. Y., and Liu, L. (2012). Drug discovery enters a new era with multi-target intervention strategy. Chin. J. Integr. Med. 18, 539-542. doi: 10.1007/s11655-011-0900-2
102. Tossi, A., and Sandri, L. (2002). Molecular diversity in gene-encoded, cationic antimicrobial polypeptides. Curr. Pharm. Des. 8, 743-761. doi: 10.2174/1381612023395475
103. Udekwu, K. I., Parrish, N., Ankomah, P., Baquero, F., and Levin, B. R. (2009). Functional relationship between bacterial cell density and the efficacy of antibiotics. J. Antimicrob. Chemother. 63, 745-757. doi: 10.1093/jac/dkn554
104. Velden, W. J. F. M. V. D., van Iersel, T. M. P., Blijlevens, N. M. A., and Donnelly, J. P. (2009). Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med. 7:44. doi: 10.1186/1741-7015-7-44
105. Wright, G. D. (2009). Making sense of antisense in antibiotic drug discovery. Cell Host Microbe 6, 197-198. doi: 10.1016/j.chom.2009.08.009
106. Wu, W., Huang, J., Duan, B., Traficante, D. C., Hong, H., Risech, M., et al. (2012). Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 186, 420-427. doi: 10.1164/rccm.201202-0182OC
107. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabási, A. L., and Vidal, M. (2007). Drug-target network. Nat. Biotechnol. 25, 1119-1126. doi: 10.1038/nbt1338
108. Yu, P., van der Linden, D. S., Sugiarto, H., and Anderson, R. C. (2010). Antimicrobial peptides isolated from the blood of farm animals. Anim. Prod. Sci. 50, 660-669. doi: 10.1071/EA07185
109. Zhang, W., and Sack, D. A. (2015). Current progress in developing subunit vaccines against enterotoxigenic Escherichia coli-associated diarrhea. Clin. Vaccine Immunol. 22, 983-991. doi: 10.1128/CVI.00224-15